Efficacy of Repetitive Transcranial Magnetic Stimulation Over the Primary Cortex in Patients With Neuropathic Pain and Cancer

Inclusion Criteria: * Patient affiliated to or entitled under a social security scheme * Patient who has received informed information about the study and who has co-signed, with the investigator, a consent form to participate in the study. * Patient aged 18 to 85 (male or female), * Central or peripheral neuropathic pain related to cancer and/or its treatment; * Chronic pain (present for more than 4 months) whose intensity is greater than or equal to 4/10 on a VAS (Visual Analogue Scale) numerical scale. * Pain present on a daily or almost daily basis (at least 4 days a week) * Patient not completely relieved by recommended first- and second-line drug treatments for neuropathic pain * Stable analgesic treatment (no new treatment or dosage adjustment) for at least one month and will not need to be modified for the duration of the study. * Patient can be followed throughout the study. * Indication for rTMS of the motor cortex by a neurologist. Exclusion Criteria: * Accident at work or litigation, * Contraindication to rTMS or MRI (treatment with seismotherapy during the previous month; history of cranial trauma; intracranial hypertension; intracerebral metal clip; piercing; pacemaker; insulin pump; metal prosthesis; pregnant or breast-feeding woman; claustrophobia). * Chronic alcoholism * Abuse of drugs or psychoactive substances * Neuropathic pain as part of a progressive pathology (e.g. HIV), * Presence of other pain of greater intensity than the neuropathic pain leading to inclusion * Acute stroke (\< 3 months) * Patient with brain tumour lesions * Patient with infectious or metabolic brain lesions * Patients with severe or recent cardiac disorders * Patients with cognitive impairment * Patient unable to understand informed consent, * Patients refusing to stop or unable to stop treatments prohibited during the study, such as morphine. * Patients participating in another research protocol involving a medicinal product within 30 days prior to inclusion. * Patients deprived of their liberty or under legal protection (guardianship, curatorship, safeguard of justice, family habilitation).